ColoSense
Geneoscopy, Inc. · Decision date Sep 15, 2025
What did the FDA approve?
FDA records P230001/S009 as a supplement to PMA P230001, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Sep 15, 2025.
FDA approval order statement
Submission is approved.
- Regulatory pathway
- PMA supplement
- Supplement type
- Real-Time Process
- Clinical specialty
- Pathology
- Decision date
- Sep 15, 2025
- FDA change category
- Labeling Change - Indications/instructions/shelf life/tradename
Regulatory record facts
- Identifier
- P230001/S009
- Regulatory pathway
- PMA supplement
- Applicant
- Geneoscopy, Inc.
- Product code
- SBB
- Decision code
- APPR
- Decision date
- Sep 15, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: System, Colorectal Neoplasia, RNA Markers and Hemoglobin detection.
- Applicant
- Geneoscopy, Inc.
- Product code
- SBB
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P230001. Subsequent supplements may change the device or its indications.
FDA decision timeline
P230001 · Original PMA
ColoSense
P230001/S009 received
Application receipt date recorded by FDA.
P230001/S010 · Related supplement
ColoSense
P230001/S009 · FDA decision
Real-Time Process
P230001/S011 · Related supplement
ColoSense
P230001/S012 · Related supplement
ColoSense
P230001/S014 · Related supplement
ColoSense
Timeline entries are records held by MedtechLedger for P230001. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P230001
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ColoSenseP230001 | Geneoscopy, Inc. | PMA approval | May 3, 2024 | FDA |
ColoSenseP230001/S010 | Geneoscopy, Inc. | PMA supplement | Aug 14, 2025 | FDA |
ColoSenseP230001/S011 | Geneoscopy, Inc. | PMA supplement | Oct 24, 2025 | FDA |
ColoSenseP230001/S012 | Geneoscopy, Inc. | PMA supplement | Aug 27, 2026 | FDA |
ColoSenseP230001/S014 | Geneoscopy, Inc. | PMA supplement | Sep 8, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Geneoscopy, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 2220 Welsch Industrial Ct., St. Louis, MO, 63146
Sources and methodology
- Original FDA record: P230001/S009
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


